About Bioline  All Journals  Testimonials  Membership  News  Donations

Indian Journal of Cancer
Medknow Publications on behalf of Indian Cancer Society
ISSN: 0019-509X
EISSN: 0019-509X
Vol. 47, No. 4, 2010, pp. 443-451
Bioline Code: cn10104
Full paper language: English
Document type: Review Article
Document available free of charge

Indian Journal of Cancer, Vol. 47, No. 4, 2010, pp. 443-451

 en Biological response modifiers: Current use and future prospects in cancer therapy
Bisht, M; Bist, S. S. & Dhasmana, D. C.


Over the past few decades, considerable success has been achieved in the field of cancer treatment with biological response modifiers (BRM), which are agents that improve the body′s ability to fight cancer by immunostimulation. Biological agents, such as interferons and interleukins, provide nonspecific active immunity, whereas the monoclonal antibodies provide passive immunity. Apart from this, other biological agents, such as antiangiogenic agents, matrix metalloprotease inhibitors, tyrosine kinase inhibitors, and tumor vaccines, are also increasingly being used in cancer treatment. Hematopoietic factors, such as granulocyte colony-stimulating factor, are used to increase the general immunity and prevent opportunistic infection. BRM are basically used alone or as adjuvants to cancer chemotherapeutic agents. This review sheds light on the current use and the future development of cancer immunotherapy. Search strategy included Pubmed, using the terms "Biological response modifiers in cancer" citations relevant to the topic were screened.

Biological response modifiers, cancer, monoclonal antibodies

© Copyright 2010 Indian Journal of Cancer.
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2022, Site last up-dated on 27-Jul-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil